Tech Company Financing Transactions

Loxo Oncology Funding Round

Loxo Oncology closed a $24 million Series B financing round on 5/6/2014. Investors included New Enterprise Associates, Aisling Capital and OrbiMed.

Transaction Overview

Company Name
Loxo Oncology
Announced On
5/6/2014
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Series B
Investors

New Enterprise Associates (Lead Investor) (James Barrett)

Aisling Capital (Dov Goldstein)

OrbiMed (David Bonita)

Proceeds Purpose
With the proceeds from this financing, we are now in an even stronger position to advance our lead asset LOXO-101, currently in a Phase 1 dose escalation trial, and to expand our exciting discovery pipeline.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
281 Tresser Blvd. 9th Floor
Stamford, CT 06901
USA
Phone
(203) 653-3880
Website
www.loxooncology.com
Email Address
[email protected]
Overview
Loxo Oncology was founded by Josh Bilenker, M.D., a partner at Aisling Capital. Loxo Oncology is committed to bringing targeted cancer therapies rapidly into the clinic that have an opportunity for outsized clinical effects in genetically defined patient populations.
Profile
Loxo Oncology LinkedIn Company Profile
Social Media
Loxo Oncology Company Twitter Account
Company News
Loxo Oncology News
Facebook
Loxo Oncology on Facebook
YouTube
Loxo Oncology on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Josh Bilenker
  Josh Bilenker LinkedIn Profile  Josh Bilenker Twitter Account  Josh Bilenker News  Josh Bilenker on Facebook
Chief Medical Officer
Nora Ku
  Nora Ku LinkedIn Profile  Nora Ku Twitter Account  Nora Ku News  Nora Ku on Facebook
Vice President
Christopher Pierce
  Christopher Pierce LinkedIn Profile  Christopher Pierce Twitter Account  Christopher Pierce News  Christopher Pierce on Facebook
VP - Bus. Development
Jacob Naarden
  Jacob Naarden LinkedIn Profile  Jacob Naarden Twitter Account  Jacob Naarden News  Jacob Naarden on Facebook
VP - Bus. Development
Nisha Nanda
  Nisha Nanda LinkedIn Profile  Nisha Nanda Twitter Account  Nisha Nanda News  Nisha Nanda on Facebook
VP - Finance
Jennifer Burstein
  Jennifer Burstein LinkedIn Profile  Jennifer Burstein Twitter Account  Jennifer Burstein News  Jennifer Burstein on Facebook
VP - Human Resources
Jennifer Kronick
  Jennifer Kronick LinkedIn Profile  Jennifer Kronick Twitter Account  Jennifer Kronick News  Jennifer Kronick on Facebook
VP - Operations
Sara Slifka
  Sara Slifka LinkedIn Profile  Sara Slifka Twitter Account  Sara Slifka News  Sara Slifka on Facebook
VP - R & D
Michael Rothenberg
  Michael Rothenberg LinkedIn Profile  Michael Rothenberg Twitter Account  Michael Rothenberg News  Michael Rothenberg on Facebook
VP - Regulatory Affairs
Deborah Morosini
  Deborah Morosini LinkedIn Profile  Deborah Morosini Twitter Account  Deborah Morosini News  Deborah Morosini on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/6/2014: Perfecto Mobile venture capital transaction
Next: 5/6/2014: Top Hat venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to document every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.